iPSCs: Induced Back to Controversy  by Panopoulos, Athanasia D. et al.
Cell Stem Cell
PreviewsiPSCs: Induced Back to ControversyAthanasia D. Panopoulos,1 Sergio Ruiz,1 and Juan Carlos Izpisua Belmonte1,2,*
1Gene Expression Laboratory, The Salk Institute for Biological Studies, 10010 North Torrey Pines, La Jolla, CA 92037, USA
2Center of Regenerative Medicine in Barcelona, Dr. Aiguader, 88, 08003 Barcelona, Spain
*Correspondence: belmonte@salk.edu or izpisua@cmrb.eu (J.C.I.B.)
DOI 10.1016/j.stem.2011.03.003
Several recent reports (Mayshar et al., 2010; Laurent et al., 2011; Lister et al., 2011; Gore et al., 2011; Hussein
et al., 2011) uncover genetic and epigenetic alterations in induced pluripotent stem cells, stimulating debate
about their future. However, will these important findings really impact what we hope to gain?During embryonic development, differen-
tiation of embryonic stem cells (ESCs)
results in a loss of lineage potential as
cells become more committed and
functionally restricted. This process was
always thought to be unidirectional.
However, the discovery that somatic cells
could be reprogrammedback to apluripo-
tent state (induced pluripotent stem cells,
or iPSCs) after the transduction of four
defined transcription factors forever
altered our initially restricted view of
cellular plasticity (Takahashi and Yama-
naka, 2006). This discovery raised a
number of new questions: what are the
consequences, if any, of this reprogram-
ming process? Are the genome and/or
the epigenome compromised during
these cellular conversions? Are the re-
programmed cellular products function-
ally identical to their normal counterparts?
Do iPSCs undergo additional adaptation
to their culture environment? Here, we
highlight recent findings that have ad-
dressed some of these questions, and
discuss their relevance to the fate of
iPSC and ESC research.
While initial reports demonstrated the
overall similarities between iPSCs and
their ESC counterparts (reviewed in
Hanna et al., 2010), recent studies have
revealed that intricate genomic differ-
ences exist between these pluripotent
populations. In one example, an extensive
single-nucleotide polymorphism (SNP)
analysis of ESCs and iPSCs showed
that pluripotent cells have an increased
overall frequency of subchromosomal
copy number variations (CNVs) relative
to several nonpluripotent samples (Lau-
rent et al., 2011). Interestingly, ESCs
harbor large numbers of duplications
within a small subset of samples, whereas
iPSCs displayed moderate numbers of
deletions throughout several iPSC lines.CNVs were present in pluripotency-asso-
ciated genes and were influenced by
culture length and conditions, as well as
differentiation. Extended culture of iPSCs
was linked to duplications of oncogenic
genes, whereas reprogramming was
associated with tumor-suppressor gene
deletions (Laurent et al., 2011). A separate
study by Hussein et al. (2011) used a high
resolution SNP array to uncover a large
number of CNVs in iPSCs, which were
2-fold higher than the levels present in
their parental fibroblast cells or in ESCs.
They further showed that a group of novel
CNVs occur during the process of re-
programming and that recurring deletions
were observed more frequently in
common fragile sites (CFSs), suggesting
that replicative stress may contribute to
the accumulation of novel CNVs present.
Perhaps unexpectedly, Hussein and col-
leagues found that a majority of the de
novo CNVs render iPSCs selectively
disadvantaged, since intermediate pas-
sage iPSCs harbor fewer CNVs relative
to low passage iPSCs. Using global
gene expression meta-analysis, Mayshar
et al. (2010) also identified partial and
full chromosome aberrations in a large
number of ESCs and iPSCs. Finally,
Gore et al. (2011) performed exome
sequencing on several human iPSC lines
generated from fibroblasts using a variety
of reprogramming methods. They found
an average of five point mutations in
each iPSC line analyzed, independent
of the reprogramming technology used
(e.g., integrative versus nonintegrative
methods). Although the mutations were
found to be in cancer-related genes,
gene ontology analysis did not reveal
any pathway enrichments, suggesting
that the acquisition of mutations may be
a random process, rather than a selective
one. Collectively, these findings demon-Cell Stem Cstrate that both ESCs and iPSCs contain
and/or acquire genetic abnormalities.
The origin of these genomic alterations
in iPSCs was attributed to their pre-exis-
tence in the parental somatic cells or
their occurrence during reprogramming.
Additionally, culture adaptations can con-
tribute to these aberrations for both ESCs
and iPSCs.
Although initial DNA and histone meth-
ylation analyses demonstrated that iPSCs
are markedly similar, but not identical, to
ESCs (reviewed in Hanna et al., 2010),
Lister et al.’s recent report of single-base
resolution whole-genome profiles of
several iPSC and ESC lines provides a
more complete picture of the existing
epigenetic differences. Thiswork revealed
over a thousand differentially methylated
regions (DMRs) between iPSC and ESC
lines, categorized as either due to failure
to completely reprogram the somatic
methylation pattern (epigenetic memory)
or as new acquired methylation patterns
(epigenetic mutation). Importantly, they
identified a core set of DMRs that seem
to represent hotspots of failed epigenomic
reprogramming, as well as megabase-
scale regions of aberrant non-CG methyl-
ation in all of the iPSC lines analyzed. They
also observed that some of the DMRs
observed in iPSCs are transmitted to
differentiated cell progeny (Lister et al.,
2011). It is worth noting that aberrant
epigenetic alterations are not exclusive
to transcription factor-dependent reprog-
ramming. For example, even after somatic
cell nuclear transfer (considered the gold
standard procedure for reprogramming),
evidence of ectopically expressed
donor-specific genes can be found within
various lineages in the developing embryo
(Ng and Gurdon, 2005).
These combined recent findings leave
us with several questions. What causesell 8, April 8, 2011 ª2011 Elsevier Inc. 347
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Previewsthese genetic and epigenetic alterations?
Will they have functional consequences
in vivo? Can we distinguish between
harmless and deleterious differences?
Will it be possible to derive iPSCs free of
these aberrancies? Will it matter in the
end?
Detection of these genomic/epigenetic
differences was made possible by the
development of high-throughput se-
quencing technologies and by the gener-
ation of single-nucleotide genome-wide
maps of DNA methylation. In time, these
technologies will likely become even
more sensitive and affordable, thus
enabling additional analyses of iPSC lines
derived and maintained under a variety of
conditions. Furthermore, the complete
genetic and epigenetic profiles of mature
cells obtained via transcription-depen-
dent transdifferentiation, or of iPSCs
generated by new methodologies, such
as the miRNA-mediated reprogramming
protocol described in this issue of Cell
Stem Cell (Anokye-Danso et al., 2011),
have yet to be examined. Extending the
analyses to at least these lengths will be
required to determine whether reprog-
rammed cells can be derived free of, or
containing minimal, genetic alterations.
Perhaps more emphasis should be
placed, however, on examining the func-
tional consequences of genetic alter-
ations present in ESCs/iPSCs. For
instance, it is still unclear if the few,
possibly random, protein-coding muta-
tions in iPSCs (Gore et al., 2011) will result
in an altered cellular or oncogenic pheno-
type. In fact, decades of cancer research
have established that a series of muta-
tions is required to produce an oncogenic
phenotype in vivo. The functional implica-
tions of epigenetic aberrations present
in iPSCs are also still largely open to
question. There is some evidence that
epigenetic memory can positively affect
differentiation potential (reviewed in
Hanna et al., 2010), but it is unclear
whether epigenetic aberrations will lead
to any negative functional consequences.
Even without knowing the functional
implications, let us consider if these
observed genetic and epigenetic alter-348 Cell Stem Cell 8, April 8, 2011 ª2011 Elsations matter. Consider, for instance,
that allogeneic bone marrow transplanta-
tions have been utilized successfully for
decades, yet it is likely that the donor’s
hematopoietic cells contain mutations.
Furthermore, it seems probable that clin-
ical use of iPSCs will be applied to treat
diseases with high morbidity or mortality
rates, for which there are currently limited
or no clinical alternatives. In fact, clinical
trials using oligodendrocytes differenti-
ated from human ESCs (obtained from
non HLA-matched common stem cell
lines) have already begun for patients
with recent paralysis due to spinal cord
injury (Strauss, 2010). Although this trial
is controversial even within the scientific
community, the patients opt to receive
this treatment despite the associated
risks, even though their sustained injuries
are not life threatening. Thus, for specific
disease cases where there is no alter-
native, the unknown long-term conse-
quences that could accompany iPSC
therapies, such as the possibility of devel-
oping cancer, may not supersede the
possible benefit for the patient.
Additionally, given that clinical thera-
pies would likely use cells differentiated
from iPSCs (e.g., hematopoietic stem
cells with a genetic correction), it may be
more relevant to clarify which abnor-
malities will be present in the various
downstream populations, rather than the
pluripotent cells themselves. Although
some evidence that genetic and epige-
netic aberrations can persist and/or occur
during differentiation protocols has been
presented (Laurent et al., 2011; Lister
et al., 2011), a more extensive examina-
tion is warranted, since protocols will
likely differ in their capacity to generate
and/or maintain such variations. Impor-
tantly, in some cases, these differentiated
cell types may be short-lived in vivo,
limiting any possible deleterious conse-
quences. Moreover, mutagenic events
that affect pluripotent cell populations
may be inconsequential to mature/differ-
entiated cell functions.
Regardless of the future for iPSCs in
the clinic, the development of iPSC tech-
nologies has also provided methods ofevier Inc.obtaining pluripotent cells from poorly
understood or largely inaccessible disor-
ders. Many disease-specific iPSCs have
already been generated, which will not
only allow us to recapitulate and study
the disease phenotypes in vitro, but also
enable screening for therapeutic candi-
dates to minimize or prevent disease
onset and/or development.
Just as scientists remember how our
initially restricted view of plasticity was
uprooted by Yamanaka’s demonstration
of reprogramming, we ask ourselves,
should these recent findings detract
from what we are aiming to gain? Let us
not decide too quickly for a field that has
more promise and unknowns than
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